Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) EPS (Basic) (2018 - 2025)

Historic EPS (Basic) for Inmune Bio (INMB) over the last 7 years, with Q3 2025 value amounting to -$0.24.

  • Inmune Bio's EPS (Basic) rose 6000.0% to -$0.24 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.12, marking a year-over-year increase of 275.23%. This contributed to the annual value of -$2.14 for FY2024, which is 2800.62% down from last year.
  • Inmune Bio's EPS (Basic) amounted to -$0.24 in Q3 2025, which was up 6000.0% from -$1.05 recorded in Q2 2025.
  • Inmune Bio's EPS (Basic)'s 5-year high stood at -$0.24 during Q3 2025, with a 5-year trough of -$1.05 in Q2 2025.
  • Over the past 5 years, Inmune Bio's median EPS (Basic) value was -$0.44 (recorded in 2021), while the average stood at -$0.47.
  • Over the last 5 years, Inmune Bio's EPS (Basic) had its largest YoY gain of 6000.0% in 2025, and its largest YoY loss of 11000.0% in 2025.
  • Quarter analysis of 5 years shows Inmune Bio's EPS (Basic) stood at -$0.56 in 2021, then soared by 42.84% to -$0.32 in 2022, then tumbled by 46.87% to -$0.47 in 2023, then dropped by 0.99% to -$0.47 in 2024, then soared by 49.44% to -$0.24 in 2025.
  • Its last three reported values are -$0.24 in Q3 2025, -$1.05 for Q2 2025, and -$0.43 during Q1 2025.